Subodh Saggi, MD
Nephrology · Brooklyn, NYNPI 1952399693
Payments from drug & device makers
What this record shows
This record is dominated by education: $407 of the $547 with a category attached, or 74.3%. Otsuka America Pharmaceutical, Inc. accounts for 78.4% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2020 at $417 and has fallen 95.3% since, to $20 in 2025. That places this record below the midpoint for nephrology clinicians in NY, where the typical reported total is $564.
Across 11 payments — averaging $49.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$429
- Vifor Pharma, Inc.$39
- Calliditas Therapeutics US Inc.$25
- Amarin Pharma, Inc.$20
- Mozarc Medical US LLC$20
- Nuwellis, Inc.$15
Across 77 payments — averaging $5445.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$221K
- Vertex$153K
- Aurinia Pharma U.S., Inc.$24K
- Boehringer Ingelheim International GmbH$19K
- CSL Behring$2K
What the payments were for
- Food & beverage$14026%
- Education$40774%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 5 | $429 |
| Vifor Pharma, Inc. | 2 | $39 |
| Calliditas Therapeutics US Inc. | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $20 |
| Mozarc Medical US LLC | 1 | $20 |
| Nuwellis, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JYNARQUE$191
How this compares
$547 in reported general payments places this provider in the 45th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 15 | $25,308 |
| RayaldeeCalcifediol | 12 | $24,627 |
| FarxigaDapagliflozin Propanediol | 22 | $19,538 |
| JanuviaSitagliptin Phosphate | 11 | $11,625 |
| ProsolParenteral Amino Acid 20% No.1 | 33 | $5,585 |
| Cinacalcet Hcl | 11 | $2,534 |
| Hydralazine Hcl | 18 | $777 |
| Nifedipine ErNifedipine | 18 | $598 |
| Calcitriol | 12 | $433 |
| Losartan Potassium | 23 | $355 |
| Rosuvastatin Calcium | 19 | $144 |
| Chlorthalidone | 14 | $127 |
| Atorvastatin Calcium | 14 | $114 |
| Furosemide | 13 | $53 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Brooklyn
- Alexander SwanBrooklyn$172K
- George NeidermanBrooklyn$109K
- Gregg MillerBrooklyn$54K
- Kalyana JangaBrooklyn$35K
- Payam ShakouriPoughkeepsie$930K
- Gerald AppelNew York$842K
- Richard ChanNew York$514K
- Bruce SpinowitzBronx$465K
- Steven CocaNew York$445K
- Joseph RoglieriTroy$425K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.